

Edgar Filing: AVENTIS - Form 425

AVENTIS
Form 425
February 02, 2004

Filed by Sanofi-Synthelabo
Pursuant to Rule 135 and Rule 425(b) under the
United States Securities Act of 1933,
as amended, and deemed filed pursuant to Rule 14d-2(b)(2) of the
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis
Commission File No. 001-10378
Date: February 2, 2004

ON FEBRUARY 2, 2004, THE FOLLOWING TWO ADVERTISEMENTS WERE PUBLISHED ON
BEHALF OF SANOFI-SYNTHELABO IN THE FINANCIAL TIMES EUROPEAN EDITION AND THE
INTERNATIONAL HERALD TRIBUNE EUROPEAN EDITION.

* * * *

WE REFUSE TO ACCEPT THAT SCIENTISTS
DO NOT WORK TOGETHER
TO SPEED UP THEIR RESEARCH.

[Close-up image of old man leaning on walking stick]

In an essential field such as healthcare, we must do everything possible to move faster. The coming together of Sanofi-Synthelabo and Aventis means thousands of scientists throughout the world working towards a common goal and combatting diseases more effectively. Our project will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS
BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell, or an offer to purchase, any securities

www.sanofi-synthelabo.com

WE REFUSE TO ACCEPT THAT
WE CANNOT DEVELOP MEDICINES
FOR TOMORROW JUST BECAUSE OF OUR SIZE.

[Image of young girl looking upward]

Out of every 100,000 molecules screened only one becomes a new drug. Research is a major investment: it takes an average of 12 years and 800 million euros to obtain a medicine. That is why teaming up with Aventis will help us deliver more

Edgar Filing: AVENTIS - Form 425

effective solutions to meet patients' needs. Together, we will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell, or an offer to purchase, any securities

www.sanofi-synthelabo.com